| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ACN; BANF; Merlin; Moesin ezrin radixin like protein; Neurofibromatosis 2; Neurofibromin 2; Nf2; SCH; Schwannomerlin |
| Entrez GeneID | 4771 |
| WB Predicted band size | Calculated MW: 70 kDa; Observed MW: 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human NF2/Merlin |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于NF2抗体的3篇参考文献及其简要摘要：
1. **《Merlin: A tumour suppressor linked to multiple membrane-associated processes》**
- **作者**: Bretscher, A., Edwards, K., & Fehon, R.G.
- **摘要**: 研究Merlin蛋白(NF2基因产物)的结构域功能，利用特异性抗体验证其在细胞膜上的定位及与细胞骨架的相互作用，揭示其抑癌机制。
2. **《Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4DCAF1》**
- **作者**: Lallemand, D., Curto, M., & McClatchey, A.I.
- **摘要**: 通过Western blot和免疫沉淀实验，使用NF2抗体证明Merlin通过调控CRL4DCAF1复合物抑制肿瘤发生，阐明其分子通路。
3. **《The NF2 tumor suppressor regulates cell-cell adhesion by controlling vinculin ubiquitination》**
- **作者**: Cooper, J., & Giancotti, F.G.
- **摘要**: 采用NF2特异性抗体进行免疫荧光分析，揭示Merlin通过调控黏着斑蛋白泛素化维持细胞间黏附，为肿瘤转移机制提供新见解。
4. **《Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2》**
- **作者**: Rouleau, G.A., et al.
- **摘要**: 首次克隆NF2基因并制备特异性抗体，验证其在患者组织中的表达缺失，奠定后续抗体在诊断和机制研究中的应用基础。
以上文献均涉及NF2抗体的实验应用(如检测、定位或机制研究)，涵盖基础研究与临床关联方向。
Neurofibromatosis type 2 (NF2) is a rare genetic disorder caused by mutations in the *NF2* tumor suppressor gene located on chromosome 22q12.2. This gene encodes merlin (or schwannomin), a cytoskeletal protein critical for regulating cell growth, adhesion, and signaling. NF2 antibodies are immunological tools designed to detect merlin expression, aiding in research and diagnostics. Loss of merlin function due to *NF2* mutations disrupts contact-dependent inhibition of proliferation, leading to benign tumors in the nervous system, such as schwannomas, meningiomas, and ependymomas.
NF2 antibodies are widely used in Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study merlin's expression patterns, subcellular localization, and interactions with binding partners (e.g., CD44. EGFR). These antibodies help identify merlin deficiency in tumor tissues, supporting NF2 diagnosis and mechanistic studies. Commercially available NF2 antibodies vary in host species, clonality, and epitope specificity, requiring validation for experimental reliability. Research using NF2 antibodies has also explored therapeutic strategies, including gene therapy and Hippo pathway modulation, to restore merlin function or target downstream effectors. Despite progress, challenges remain in understanding merlin's pleiotropic roles and developing targeted therapies for NF2-related tumors.
×
